UnknownPhase 4NCT00705588

Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rabin Medical Center
Principal Investigator
Mordechai R Kramer, MD
Rabin Medical Center
Intervention
Tadalafil(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2008

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00705588 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials